Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
160.50
+0.25 (0.16%)
At close: Nov 13, 2026, 4:00 PM EST
160.78
+0.28 (0.17%)
After-hours: Nov 13, 2026, 7:39 PM EST
Novartis AG Market Cap
Novartis AG has a market cap or net worth of $302.07 billion as of November 13, 2026. Its market cap has increased by 18.56% in one year.
Market Cap
302.07B
Enterprise Value
341.66B
1-Year Change
18.56%
Global Rank
n/a
Country Rank
n/a
Category
ChartMarket Cap Chart
Since April 11, 2001, Novartis AG's market cap has increased from $116.62B to $302.07B, an increase of 159.02%. That is a compound annual growth rate of 3.79%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 13, 2026 | 304.31B | 14.60% |
| Dec 31, 2025 | 265.54B | 36.49% |
| Dec 31, 2024 | 194.55B | -6.26% |
| Dec 29, 2023 | 207.54B | 5.57% |
| Dec 30, 2022 | 196.59B | 0.47% |
| Dec 31, 2021 | 195.68B | -9.46% |
| Dec 31, 2020 | 216.12B | -1.25% |
| Dec 31, 2019 | 218.84B | 10.05% |
| Dec 31, 2018 | 198.86B | -0.23% |
| Dec 29, 2017 | 199.33B | 15.27% |
| Dec 30, 2016 | 172.91B | -16.21% |
| Dec 31, 2015 | 206.38B | -8.20% |
| Dec 31, 2014 | 224.80B | 15.54% |
| Dec 31, 2013 | 194.57B | 27.72% |
| Dec 31, 2012 | 152.34B | 16.39% |
| Dec 30, 2011 | 130.89B | -2.38% |
| Dec 31, 2010 | 134.07B | 8.76% |
| Dec 31, 2009 | 123.28B | 9.40% |
| Dec 31, 2008 | 112.68B | -11.65% |
| Dec 31, 2007 | 127.53B | -4.95% |
| Dec 29, 2006 | 134.18B | 5.35% |
| Dec 30, 2005 | 127.36B | 2.12% |
| Dec 31, 2004 | 124.72B | 9.81% |
| Dec 31, 2003 | 113.58B | 7.17% |
| Dec 31, 2002 | 105.97B | 0.63% |
View and export this data all the way back to 2001. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 691.50B |
| AbbVie | 522.03B |
| Merck & Co. | 361.45B |
| AstraZeneca | 287.75B |
| Amgen | 251.51B |
| Gilead Sciences | 208.80B |
| Novo Nordisk | 181.47B |
| Pfizer | 163.53B |